CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 7 enrolled
Drug / intervention
florbetapir (18F)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01660815
NCT01660815Phase 1Completed
CompareCT.gov

PET Whole Body Biodistribution Using Florbetapir (18F)

Avid Radiopharmaceuticals·interventional·Posted Aug 9, 2012·Updated Sep 19, 2013

In Brief

A Phase 1 clinical trial evaluating florbetapir (18F) for Alzheimer's Disease. Completed, enrolled 7 participants across 1 site.

Detailed Summary

This study will determine how florbetapir (18F) (18F-AV-45) radioactivity is distributed throughout the body of Japanese subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesJapan
CollaboratorsEli Lilly and Company

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2012
Enrollment StartAug 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.9 years ago

Interventions

florbetapir (18F)drug

IV injection, 370 MBq (10mCi), single dose